Improved survival of patients with advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy

Benasso, Marco; Corvò, Renzo; Cavallari, Monica; Sanguineti, Giuseppe; Margarino, G; Rosso, Riccardo; Vitale, Vito; Merlano, Marco

doi:10.1007/978-2-8178-0765-2_61

Cited by 2 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this study and the 2004 trial from Benasso et al reported an important decrease in hematologic toxicity (grade 3-4 neutropenia) compared with the first Benasso et al study from 2001, there was no major change in nonhematologic (local) toxicity [49][50][51]. Moreover, in the 2004 and 2006 trials, 2 patients and 1 patient, respectively, died during the treatment as result of neutropenic fever, leading to toxic death rates of 2% and 7% [50,51].…”

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 49%

“…), whereas higher weekly dosages of gemcitabine ($50 mg/m 2 ) during chemoradiation in patients with SCCHN lead to unacceptable toxicity rates [31, [39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54].…”

Section: Discussionmentioning

confidence: 99%

“…Using standard fractionated radiotherapy, researchers from Brazil selected weekly applications of very low-dose gemcitabine (10 mg/m 2 ) and moderately low doses of cisplatin (30 mg/m 2 ) as the recommended dosages for further study in phase II [53]. of low-dose cisplatin plus 5-fluorouracil chemotherapy [49][50][51][52]. Interestingly, these investigators also reported that the addition of gemcitabine at these low doses seemed to improve outcome.…”

Section: Discussionmentioning

confidence: 99%

“…In a feasibility study by Benasso et al, alternating chemoradiation with cisplatin and gemcitabine (800 mg/m 2 ) was responsible for an unacceptably high incidence of toxicity (mostly hematologic and mucosal), leading to 3 treatmentrelated deaths and necessitating dose reductions of gemcitabine in 79% of patients [49].…”

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 99%

“…In terms of the CR rate, the difference between very low-dose and higher-dose gemcitabine did not reach statistical significance (p 5 .087). Correspondingly, based on survival data provided in 8 studies testing higher-dose gemcitabine, a 3-year overall survival ranged from 27% to 63% [41,43,[45][46][47][49][50][51].…”

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 99%

See 4 more Smart Citations

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

Background. Platinum-based concurrent chemoradiation (CCRT) improves locoregional control and overall survival of locoregionally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) when compared to radiotherapy alone, but this approach is hampered by significant toxicity. Therefore, alternative ways to enhance the radiation effects are worth investigating. Gemcitabine (29,29-difluorodeoxycytidine), in addition to its activity against a variety of solid tumors, including SCCHN, is one of the most potent radiosensitizers, and it has an overall favorable safety profile. In this paper, the clinical experience with gemcitabine-based chemoradiation in the treatment of patients with LA-SCCHN is reviewed. Methods. We conducted a review of the literature on the clinical experience with radiotherapy combined with either single-agent gemcitabine or gemcitabine/cisplatin-based polychemotherapy for the treatment of patients with LA-SCCHN. We also searched abstracts in databases of major international oncology meetings from the last 20 years. A meta-analysis was performed to calculate pooled proportions with 95% confidence intervals (CIs) for complete response rate and grade 3-4 acute mucositis rate.

show abstract

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 99%

Section: Studies Reporting On Chemoradiation With Gemcitabine As Partmentioning

confidence: 99%

See 3 more Smart Citations

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.

th¹,

Murthy²,

Vannetzel³

et al. 1994

JCO

183

View full text Add to dashboard Cite

show abstract

Improved survival of patients with advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy

Cited by 2 publications

References 2 publications

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis

Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.

Contact Info

Product

Resources

About